What's in Your CART? Clinical insights on challenges in mononuclear cell collection for CAR‐T therapy
- 18 March 2020
- journal article
- letter
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 35 (3), 234-235
- https://doi.org/10.1002/jca.21776
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)Bone Marrow Transplantation, 2019
- Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B‐cell malignanciesTransfusion, 2019
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2018
- CMS Sets CAR-T Reimbursement Levels— Where Should the Patient Be Treated?Journal of Clinical Pathways, 2018
- Lymphocyte apheresis for chimeric antigen receptor T‐cell manufacturing in children and young adults with leukemia and neuroblastomaTransfusion, 2018
- Posttransplant chimeric antigen receptor therapyBlood, 2018
- Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsBlood, 2017
- Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapyExpert Opinion on Biological Therapy, 2017
- Biology and clinical application of CAR T cells for B cell malignanciesInternational Journal of Hematology, 2016